226 related articles for article (PubMed ID: 25726061)
21. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
Adsay NV; Basturk O; Cheng JD; Andea AA
Semin Radiat Oncol; 2005 Oct; 15(4):254-64. PubMed ID: 16183479
[TBL] [Abstract][Full Text] [Related]
22. The molecular genetics of pancreatic ductal carcinoma.
Sohn TA
Minerva Chir; 2002 Oct; 57(5):561-74. PubMed ID: 12370658
[TBL] [Abstract][Full Text] [Related]
23. Pancreatic intraepithelial neoplasia in heterotopic pancreas: evidence for the progression model of pancreatic ductal adenocarcinoma.
Zhang L; Sanderson SO; Lloyd RV; Smyrk TC
Am J Surg Pathol; 2007 Aug; 31(8):1191-5. PubMed ID: 17667542
[TBL] [Abstract][Full Text] [Related]
24. Molecular pathogenesis of pancreatic cancer.
Maitra A; Kern SE; Hruban RH
Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):211-26. PubMed ID: 16549325
[TBL] [Abstract][Full Text] [Related]
25. Bespoke treatment: drivers beware!
Pattison S; Zalcberg JR
Asia Pac J Clin Oncol; 2014 Dec; 10(4):378-80. PubMed ID: 25155963
[TBL] [Abstract][Full Text] [Related]
26. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice.
Grippo PJ; Fitchev PS; Bentrem DJ; Melstrom LG; Dangi-Garimella S; Krantz SB; Heiferman MJ; Chung C; Adrian K; Cornwell ML; Flesche JB; Rao SM; Talamonti MS; Munshi HG; Crawford SE
Gut; 2012 Oct; 61(10):1454-64. PubMed ID: 22234980
[TBL] [Abstract][Full Text] [Related]
27. Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution.
Hosein AN; Huang H; Wang Z; Parmar K; Du W; Huang J; Maitra A; Olson E; Verma U; Brekken RA
JCI Insight; 2019 Jul; 5(16):. PubMed ID: 31335328
[TBL] [Abstract][Full Text] [Related]
28. Molecular biology of pancreatic ductal adenocarcinoma.
Coleman SJ; Rhim AD
Curr Opin Gastroenterol; 2014 Sep; 30(5):506-10. PubMed ID: 25023382
[TBL] [Abstract][Full Text] [Related]
29. Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer.
Funel N; Giovannetti E; Pollina LE; del Chiaro M; Mosca F; Boggi U; Campani D
Expert Rev Mol Diagn; 2011 Sep; 11(7):695-701. PubMed ID: 21902531
[TBL] [Abstract][Full Text] [Related]
30. An unusual genomic variant of pancreatic ductal adenocarcinoma with an indolent clinical course.
Kohutek ZA; Rosati LM; Hong J; Poling J; Attiyeh MA; Makohon-Moore A; Herman JM; Iacobuzio-Donahue CA
Cold Spring Harb Mol Case Stud; 2017 Jul; 3(4):. PubMed ID: 28679692
[TBL] [Abstract][Full Text] [Related]
31. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment.
Singh P; Srinivasan R; Wig JD
Pancreas; 2011 Jul; 40(5):644-52. PubMed ID: 21673535
[TBL] [Abstract][Full Text] [Related]
32. Matrix control of pancreatic cancer: New insights into fibronectin signaling.
Topalovski M; Brekken RA
Cancer Lett; 2016 Oct; 381(1):252-8. PubMed ID: 26742464
[TBL] [Abstract][Full Text] [Related]
33. Protein kinase D enzymes: novel kinase targets in pancreatic cancer.
Liou GY; Storz P
Expert Rev Gastroenterol Hepatol; 2015; 9(9):1143-6. PubMed ID: 26174103
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic Alterations in Pancreatic Cancer Metastasis.
Wang SS; Xu J; Ji KY; Hwang CI
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439749
[TBL] [Abstract][Full Text] [Related]
35. Changing the course of pancreatic cancer--Focus on recent translational advances.
Javle M; Golan T; Maitra A
Cancer Treat Rev; 2016 Mar; 44():17-25. PubMed ID: 26924195
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer.
Shah VM; Sheppard BC; Sears RC; Alani AW
Cancer Lett; 2020 Nov; 492():63-70. PubMed ID: 32822815
[TBL] [Abstract][Full Text] [Related]
37. Macrophages and pancreatic ductal adenocarcinoma.
Habtezion A; Edderkaoui M; Pandol SJ
Cancer Lett; 2016 Oct; 381(1):211-6. PubMed ID: 26708507
[TBL] [Abstract][Full Text] [Related]
38. Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up.
Perera RM; Bardeesy N
Cancer Discov; 2015 Dec; 5(12):1247-61. PubMed ID: 26534901
[TBL] [Abstract][Full Text] [Related]
39. The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms.
Chand S; O'Hayer K; Blanco FF; Winter JM; Brody JR
Int J Biol Sci; 2016; 12(3):273-82. PubMed ID: 26929734
[TBL] [Abstract][Full Text] [Related]
40. Coordinated Transcriptional and Catabolic Programs Support Iron-Dependent Adaptation to RAS-MAPK Pathway Inhibition in Pancreatic Cancer.
Ravichandran M; Hu J; Cai C; Ward NP; Venida A; Foakes C; Kuljanin M; Yang A; Hennessey CJ; Yang Y; Desousa BR; Rademaker G; Staes AAL; Cakir Z; Jain IH; Aguirre AJ; Mancias JD; Shen Y; DeNicola GM; Perera RM
Cancer Discov; 2022 Sep; 12(9):2198-2219. PubMed ID: 35771494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
